Abstract | OBJECTIVE: STUDY DESIGN: Using a well-characterized fetal alcohol syndrome (FAS) model, timed pregnant C57BL6/J mice were treated on gestational day (E) 8 with alcohol (0.03 mL/g), placebo, or alcohol plus (NAP plus SAL). Embryos were harvested at 6 hours (E8), 24 hours (E9), and 10 days (E18) and pups at postnatal day 40. Calibrator-normalized relative real time polymerase chain reaction was performed to quantify BDNF with hypoxanthine phosphoribosyl transferase-1 standardization. RESULTS:
BDNF expression was lower in the alcohol-exposed embryos than in controls at 6 hours and higher at 24 hours and 10 days (all P<.05). Pretreatment with NAP plus SAL prevented the alcohol-induced rise in BDNF expression (P<.05) at 24 hours and 10 days after alcohol exposure. We found no difference between alcohol and control in young-adults' brain (P>.05). CONCLUSION: NAP plus SAL treatment prevented alcohol-induced changes in BDNF expression 24 hours and 10 days after alcohol exposure in mouse embryos. This may explain, at least in part, the peptides' prevention of neurodevelopmental anomalies in FAS.
|
Authors | Maddalena Incerti, Joy Vink, Robin Roberson, Ines Benassou, Daniel Abebe, Catherine Y Spong |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 202
Issue 5
Pg. 457.e1-4
(May 2010)
ISSN: 1097-6868 [Electronic] United States |
PMID | 20452488
(Publication Type: Journal Article, Research Support, N.I.H., Intramural)
|
Copyright | Copyright (c) 2010 Mosby, Inc. All rights reserved. |
Chemical References |
- Brain-Derived Neurotrophic Factor
- Neuroprotective Agents
- Oligopeptides
- seryl-alanyl-leucy-leucyl-arginyl-seryl-isoleucyl-prolyl-alanine
- davunetide
|
Topics |
- Animals
- Brain-Derived Neurotrophic Factor
(metabolism)
- Disease Models, Animal
- Female
- Fetal Alcohol Spectrum Disorders
(metabolism, prevention & control)
- Mice
- Mice, Inbred C57BL
- Neuroprotective Agents
- Oligopeptides
(pharmacology, therapeutic use)
- Pregnancy
|